Research Summary

The Pharmaceutical Biotechnology Center (PBC) addresses human and animal health concerns through development of bio-therapeutics (monoclonal antibodies, peptides, proteins) and vaccines, with emphasis on cardiometabolic diseases, diabetes and nutritional health.

The objectives are to:

  1. Establish integrated capabilities for preclinical assessment and clinical lead development of bio-therapeutics and vaccines in collaboration with academic researchers or industrial customers;
  2. Become the preferred partner and a conduit for pharmaceutical product development bridging academia and industry;
  3. Become a preferred partner for industries for the discovery as well as product and pipeline development; and
  4. Become an economic engine facilitating therapeutics development and startup businesses.

Learn about the PBC's access to Eli Lilly and Company's Fab Phage Display Library and the IBRI's other core technologies.

Lab Team

Doreen Eastes

Doreen Eastes

Research Associate, Pharmaceutical Biotechnology Center

Doreen Eastes

Doreen Eastes

Research Associate, Pharmaceutical Biotechnology Center

Doreen Eastes is a research associate in the IBRI’s Pharmaceutical Biotechnology Center (PBC), which she joined in June 2019. In this role, she is responsible for establishing hybridoma production capabilities and development of new and existing protein therapeutics.

She joined the IBRI in 2016 as a research analyst in the IBRI’s then Single Cell Analytics Center, which was phased out in the spring of 2019 to pursue external commercialization of its diagnostic platform. Prior to the IBRI, and since 2015, she was a research technician in the Wells Center for Pediatric Research at Indiana University (IU) School of Medicine in Indianapolis. Before that and since 1998, she served as an assistant diabetes research scientist at Eli Lilly and Company, Indianapolis, and then as a research associate at PreClinOmics, also in Indianapolis. Her broad scientific experience also included research at Scherling-Plough Animal Health in Mundelein, Ill., Interdisciplinary Center for Cell Products and Technologies (ICCPT) in Terre Haute, Ind., and at Pitman-Moore Inc., also in Terre Haute.

Doreen earned her B.S. in microbiology from Indiana University (IU) in Bloomington, Ind., and her M.A. in microbiology, also from IU-Bloomington.

June Javens-Wolfe, PhD

June Javens-Wolfe, PhD

Research Associate, Pharmaceutical Biotechnology Center

June Javens-Wolfe, PhD

June Javens-Wolfe, PhD

Research Associate, Pharmaceutical Biotechnology Center

June Javens-Wolfe, PhD, joined the IBRI as a Research Analyst in December 2018 in the Pharmaceutical Biotechnology Center (PBC). In her current role as Research Associate, she is responsible for the general research and development of new and existing protein therapeutics.

Prior to the IBRI and since 2015, she worked for two contractors for Eli Lilly and Company in Indianapolis – Advanced Testing Laboratory as a Biology Project Coordinator, and with Eurofins Lancaster Laboratories as a Biochemist in BioProduct Development. From 2004 to 2013, she served as a visiting research associate and graduate research assistant at Indiana University-Bloomington, Ind., and from 2013 to 2014, she held adjunct faculty positions at DePauw University in Greencastle, Ind., and at IU-Bloomington.

She has been responsible for several significant research accomplishments, including being the lead author of a research article on the cellular localization of microbial polysaccharide export proteins published in Molecular Microbiology. Dr. Javens-Wolfe earned her PhD in molecular, cellular and developmental biology from IU-Bloomington, and a BA in biology from DePauw University.

Mustapha Moussaif

Mustapha Moussaif, PhD

Senior Staff Scientist, Pharmaceutical Biotechnology Center

Mustapha Moussaif

Mustapha Moussaif, PhD

Senior Staff Scientist, Pharmaceutical Biotechnology Center

Mustapha Moussaif, Ph.D., joined the IBRI in January 2019 as Senior Staff Scientist in the Pharmaceutical Biotechnology Center (PBC).  In this role, he is responsible for establishing operational platforms for biotherapeutic antibody discovery, lead optimization and developability.

Prior to the IBRI, he worked as Scientist in the Bio-Therapeutics/Lead Engineering group with Boehringer-Ingelheim in Ridgefield, CT. Prior to that, he was a Senior Scientist in Biotherapeutics Discovery at the Icahn Medical School in Mount Sanai, NY. and worked as a Research Scientist at New York University in New York City. From 2004 to 2010, he was a Research Associated with the department of molecular pharmacology at the Albert Einstein College of Medicine in New York City.

Dr. Moussaif also served as Postdoctoral Research Associate in Biochemistry, Biophysics and Molecular Biology at the University of Iowa, Iowa City, Iowa, and as a Postdoctoral Fellow at Wayne State University in Detroit, Mich. He earned his Ph.D. in Biology and Biological Sciences from the University of Liège, Liège, Belgium, and his B.S. in Cellular and Molecular Biology from the University Abdel Malek Essaadi in Morocco. He has published and contributed to the publication of more than 15 research articles.

Timothy Richardson, PhD

Timothy Richardson, PhD

Scientific Director of Molecular Innovation

Timothy Richardson, PhD

Timothy Richardson, PhD

Scientific Director of Molecular Innovation

Timothy Richardson is a Senior Research Professor in the Department of Clinical Pharmacology at Indiana University School of Medicine where his primary responsibilities include leading the Medicinal Chemistry Core of the IUSM-Purdue TREAT-AD (Target Enablement to Accelerate Therapy Development for Alzheimer's Disease) Center.

Prior to his transition to the IU School of Medicine, he was a Research Fellow at Eli Lilly and Company. During his industrial career he contributed to discovery programs that delivered new molecular entities for the treatment of endocrine, musculoskeletal and autoimmune diseases. He led technology platform teams focused on gene regulation, epigenetics and nuclear receptors. He also served as a Group Leader in Discovery Chemistry, a role in which he guided multiple discovery teams that built a portfolio of small molecule therapeutics for the treatment of autoimmune diseases.

Dr. Richardson finished his career at Eli Lilly and Company as a founding member of the RNA Therapeutics Team focused on oligonucleotide-based medicines. 

Dr. Richardson joined the IBRI in February 2021 as Scientific Director of Molecular Innovation, where he is applying his academic and industrial experience in collaboration with institute scientists and external research partners to drive translational science that rapidly advances novel therapeutics for unmet medical needs.

Megan Sopko

Megan Sopko

Senior Research Associate, Pharmaceutical Biotechnology Center

Megan Sopko

Megan Sopko

Senior Research Associate, Pharmaceutical Biotechnology Center

Megan Sopko joined the IBRI in April 2019 as Senior Research Associate in the Pharmaceutical Biotechnology Center (PBC).  In this role, she is responsible for the general research and development of new and existing protein therapeutics.

Prior to the IBRI and since 2010, she served as a Technologist/Technician and then as a Technologist for Corteva Agriscience, the Agriculture Division of DowDuPont (formerly Dow Agrisciences) in Indianapolis. She was involved in diverse lab operations and research, and in the training of other technicians. From  2004 to 2010, she was a Lab Technician and Scientist with Kelly Scientific Resources in Indianapolis. She was involved in gene expression and other genetic research.

Megan earned her Bachelor of Science degree in Biology from the University of Minnesota in Minneapolis. She has been responsible for three scientific publications covering genetic and protein research.